https://prabadinews.com/
  • October 10, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

New ROS1+ Lung Cancer Drug Shows Positive Results for Over Half of Patients

Promising phase 2 results for tarlatamab in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

administrator

Related Articles